Probiotics Bring New Hope for Atherosclerosis Prevention and Treatment.
Tai-Yu ZhaiPingping WangXiumei HuLei ZhengPublished in: Oxidative medicine and cellular longevity (2022)
Cardiovascular disease is the leading cause of human mortality and morbidity worldwide. Atherosclerosis (AS) is the underlying pathological responsible in most acute and severe cardiovascular diseases including myocardial infarction and stroke. However, current drugs applied to the treatment of AS are not clinically effective, and there is a large residual risk of cardiovascular disease and multiple side effects. Increasing evidence supports a close relationship between microorganisms and the incidence of AS. Recent data have shown that probiotics can improve multiple key factors involved in the development and progression of AS, including cholesterol metabolism imbalance, endothelial dysfunction, proinflammatory factor production, macrophage polarization, intestinal flora disturbance, and infection with pathogenic microorganisms, and therefore probiotics have attracted great interest as a novel potential "medicine". This review is aimed at summarizing the effects of probiotics on various influencing factors, and providing valuable insights in the search for early prevention and potential therapeutic strategies for AS.
Keyphrases
- cardiovascular disease
- cardiovascular events
- type diabetes
- heart failure
- risk factors
- liver failure
- atrial fibrillation
- endothelial cells
- drug induced
- left ventricular
- metabolic syndrome
- human health
- early onset
- risk assessment
- pluripotent stem cells
- big data
- blood brain barrier
- respiratory failure
- climate change
- aortic dissection
- data analysis
- cerebral ischemia